Skip to Content
US Videos

5 Drug Firms on Cutting Edge of Innovation

These manufacturing experts look undervalued today.

Mentioned: , , , ,

Karen Andersen: Branded drugmakers have come under scrutiny for high prices and annual price increases, and the landscape for negotiating discounts with payers has become more competitive. Even though reduced pricing pressure hits the top line for drug firms, we think some drugmakers are successfully using manufacturing improvements to offset pressure on the bottom line. Overall, across the industry, we see gross margins staying relatively steady at a strong 76% over the next five years, as manufacturing improvements and very strong, 95%-plus gross margins on many differentiated and effective therapies counter increased headwinds from pricing on older products and royalty and profit share payments to partners.

Following our deep dive into drug manufacturing and gross margins at 20 narrow and wide moat drug firms under our coverage, we'd like to highlight a few names that stand out for their combination of manufacturing expertise and undervalued stocks. For example, in big pharma, Glaxo and Sanofi are both committed to more efficient continuous manufacturing practices, which are slowly being adopted across the drug industry. In biotech, Biogen, Biomarin, and Roche are all undervalued and are benefiting from novel manufacturing technologies. Biogen's improving productivity makes their ability to serve a sizable potential Alzheimer's market more feasible. BioMarin is poised to see a large gross margin improvement as new drugs launch and as the firm makes progress with novel gene therapy manufacturing. Roche's large manufacturing capacity expansion should give it the flexibility it needs to manufacture a variety of novel and complex biologics. 

Karen Andersen does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.